Latanoprost Completed Phase 4 Trials for Glaucoma, Primary Open Angle (POAG) / Ocular Hypertension Treatment

IndicationsStatusPurposePhase
CompletedTreatment4
clinicaltrials.gov IdentifierTitleDrugs
NCT0165575824-hour Control of Intraocular Pressure (IOP) in Ocular Hypertension
NCT01162603Latanoprost Versus Tafluprost: 24-hour Intraocular Pressure (IOP)
NCT0033057724-Hour Intraocular Pressure (IOP) And Blood Pressure Control In Glaucoma And Ocular Hypertension Patients
NCT03331770Efficacy and Tolerability of an Innovative Formulation of BAK-free Latanoprost